Andrei Diana, Popa Iulian, Brad Silviu, Iancu Aida, Oprea Manuel, Vasilian Cristina, Poenaru Dan V
Medical Rehabilitation and Rheumatology Department, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
Orthopaedic and Traumatology Department, Victor Babes University of Medicine and Pharmacy, 300086, Matei Corvin 3, Timisoara, Romania.
Int Orthop. 2017 May;41(5):963-968. doi: 10.1007/s00264-017-3409-2. Epub 2017 Feb 4.
Osteoporotic vertebral fractures (OVF) can lead to late collapse which often causes kyphotic spinal deformity, persistent back pain, decreased lung capacity, increased fracture risk and increased mortality. The purpose of our study is to compare the efficacy and safety of vertebroplasty against conservative management of osteoporotic vertebral fractures without neurologic symptoms.
A total of 66 patients with recent OVF on MRI examination were included in the study. All patients were admitted from September 2009 to September 2012. The cohort was divided into two groups. The first study group consisted of 33 prospectively followed consecutive patients who suffered 40 vertebral osteoporotic fractures treated by percutaneous vertebroplasty (group 1), and the control group consisted of 33 patients who suffered 41 vertebral osteoporotic fractures treated conservatively because they refused vertebroplasty (group 2). The data collection has been conducted in a prospective registration manner. The inclusion criteria consisted of painful OVF matched with imagistic findings. We assessed the results of pain relief and minimal sagittal area of the vertebral body on the axial CT scan at presentation, after the intervention, at six and 12 months after initial presentation.
Vertebroplasty with poly(methyl methacrylate) (PMMA) was performed in 30 patients on 39 VBs, including four thoracic vertebras, 27 vertebras of the thoracolumbar jonction and eight lumbar vertebras. Group 2 included 30 patients with 39 OVFs (four thoracic vertebras, 23 vertebras of the thoracolumbar junction and 11 lumbar vertebras). There was no significant difference in VAS scores before treatment (p = 0.229). The mean VAS was 5.90 in Group 1 and 6.28 in Group 2 before the treatment. Mean VAS after vertebroplasty was 0.85 in Group 1. The mean VAS at six months was 0.92 in Group 1 and 3.00 in Group 2 (p < 0.05). The mean VAS at 12 months was 0.92 in Group 1 and 2.36 in Group 2. The mean improvement rate in VAS scores was 84.40% and 62.42%, respectively (p < 0.05). For Group 1, mean area of the VBs measured on sagital CT images was 8.288 at the initial presentation, 8.554 postoperatively, 8.541 at five months and 8.508 at 12 months, respectively, and 8.388 at the initial presentation, 7.976 at six months and 7.585 at 12 months for Group 2 (Fig. 4).
Although conservative treatment is fundamental and achieves good symptom control, in patients who suffer osteoporotic compression fractures (OCF), the incidence of late collapse is high and the prognosis is poor. In order to relieve the pain and avoid VB collapse, vertebroplasty is the recommended treatment in OCFs. Considering the above findings, the dilemma is whether vertebroplasty can change the natural history (pain and deformity) of OCFs.
In our study on OVF, vertebroplasty delivered superior clinical and radiological outcomes over the first year from intervention when compared to conservative treatment of patients with osteoporotic compression fractures without neurological deficit. We believe that the possibility of evolution towards progressive kyphosis is sufficient to justify prophylactic and therapeutic intervention such as vertebroplasty, a minor gesture compared with extensive correction surgery and stabilization.
骨质疏松性椎体骨折(OVF)可导致晚期塌陷,常引起脊柱后凸畸形、持续背痛、肺功能下降、骨折风险增加及死亡率上升。我们研究的目的是比较椎体成形术与保守治疗无症状性骨质疏松性椎体骨折的疗效和安全性。
本研究纳入66例近期MRI检查发现有OVF的患者。所有患者于2009年9月至2012年9月入院。将队列分为两组。第一研究组由33例连续前瞻性随访患者组成,他们共发生40例骨质疏松性椎体骨折,接受经皮椎体成形术治疗(第1组),对照组由33例患者组成,他们共发生41例骨质疏松性椎体骨折,因拒绝椎体成形术而接受保守治疗(第2组)。数据收集采用前瞻性登记方式。纳入标准包括与影像学表现相符的疼痛性OVF。我们在初次就诊时、干预后、初次就诊后6个月和12个月评估了疼痛缓解结果以及轴向CT扫描上椎体的最小矢状面积。
30例患者对39个椎体进行了聚甲基丙烯酸甲酯(PMMA)椎体成形术,其中包括4个胸椎椎体、27个胸腰段椎体和8个腰椎椎体。第2组包括30例患者,共39例OVF(4个胸椎椎体、23个胸腰段椎体和11个腰椎椎体)。治疗前视觉模拟评分(VAS)无显著差异(p = 0.229)。治疗前第1组平均VAS为5.90,第2组为6.28。椎体成形术后第1组平均VAS为0.85。第1组6个月时平均VAS为0.92,第2组为3.00(p < 0.05)。第1组12个月时平均VAS为0.92,第2组为2.36。VAS评分平均改善率分别为84.40%和62.42%(p < 0.05)。对于第1组,矢状面CT图像上测量的椎体平均面积在初次就诊时为8.288,术后为8.554,5个月时为8.541,12个月时为8.508,第2组在初次就诊时为8.388,6个月时为7.976,12个月时为7.585(图4)。
尽管保守治疗是基础且能实现良好的症状控制,但对于患有骨质疏松性压缩骨折(OCF)的患者,晚期塌陷发生率高且预后差。为缓解疼痛并避免椎体塌陷,椎体成形术是OCF推荐的治疗方法。考虑到上述发现,困境在于椎体成形术是否能改变OCF的自然病程(疼痛和畸形)。
在我们关于OVF的研究中,与无神经功能缺损的骨质疏松性压缩骨折患者的保守治疗相比,椎体成形术在干预后的第一年提供了更好的临床和影像学结果。我们认为,发展为进行性后凸畸形的可能性足以证明预防性和治疗性干预(如椎体成形术)的合理性,与广泛的矫正手术和内固定相比,这是一个较小的手术。